[Very Severe Differentiation Syndrome in Low Risk Acute Promyelocytic Leukemia - A Peril of Differentiating Therapy]

Dtsch Med Wochenschr. 2017 Jan;142(2):111-114. doi: 10.1055/s-0042-121365. Epub 2017 Jan 23.
[Article in German]

Abstract

History, examinations and diagnosis A young patient consulted the hospital because of spontaneous hematomas. The combination of pancytopenia and coagulopathy in the blood and the proving cytogenetic and moleculargenetic examinations of the bone marrow lead to the diagnosis of low-risk acute promyelocytic leukemia (APL). Therapy and clinical course During the combination therapy with ATRA and ATO, the patient developed a severe differentiation syndrome and hyperleukocytosis. Management of the condition was only possible due to clinical expertise and massive substitution of blood products and clotting factors. Conclusion The case illustrates the difficulty and dangers of APL induction therapy even with a favorable initial clinical presentation despite the generally low toxicity of new therapies.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Arsenic Trioxide
  • Arsenicals / administration & dosage
  • Arsenicals / adverse effects
  • Diagnosis, Differential
  • Dyspnea / chemically induced*
  • Dyspnea / diagnosis
  • Dyspnea / prevention & control
  • Female
  • Fever / chemically induced*
  • Fever / diagnosis
  • Fever / prevention & control
  • Humans
  • Hypotension / chemically induced*
  • Hypotension / diagnosis
  • Hypotension / prevention & control
  • Leukemia, Promyelocytic, Acute / complications
  • Leukemia, Promyelocytic, Acute / diagnosis
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukocytosis / chemically induced
  • Leukocytosis / diagnosis
  • Leukocytosis / prevention & control
  • Lung Diseases / chemically induced*
  • Lung Diseases / diagnosis
  • Lung Diseases / prevention & control
  • Oxides / administration & dosage
  • Oxides / adverse effects
  • Risk Factors
  • Severity of Illness Index
  • Syndrome
  • Treatment Outcome
  • Tretinoin / administration & dosage
  • Tretinoin / adverse effects

Substances

  • Antineoplastic Agents
  • Arsenicals
  • Oxides
  • Tretinoin
  • Arsenic Trioxide